Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Freiburg, May 7th, 2025

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid (NCA) in primary sclerosing cholangitis (PSC).

NUC-5 (NCT03872921) is a double-blind, placebo-controlled trial enrolling 301 patients with PSC, who receive either 1,500 mg NCA or placebo for a total of 192 weeks. At the primary data analysis after 96 weeks of treatment, the primary endpoint of combined partial normalization of blood levels of a liver enzyme linked to PSC (alkaline phosphatase) and no worsening of disease stage on histology was achieved by a statistically significantly greater proportion of patients receiving NCA than placebo. Significant superiority of NCA was also observed in multiple secondary endpoints. The safety results revealed similar rates of study patients with adverse events and serious adverse events between the NCA and placebo groups.

The topline results from NUC-5 will be presented during the Late Breaker session on Saturday, May 10, 2025 at the EASL Congress in Amsterdam.

PSC is a rare, progressive disease in which the immune system attacks the bile ducts in the liver, which leads to fibrosis, or the formation of scar tissue. A considerable proportion of patients develop bile duct, liver, or colorectal cancer, while many others eventually progress to cirrhosis of the liver. No approved pharmaceutical treatment is currently available, and the most effective treatment option is liver transplantation.

“Finding a medicine that effectively treats PSC has been a challenge in the field of hepatology for decades” said Prof. Michael Trauner, Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria and principal investigator of the trial. “After so many disappointments in this space, the first positive results from a phase 3 study on PSC is a watershed moment for people with PSC, their families, physicians and the entire PSC community. The results of this study will not only advance patient care but will also give researchers new insights into the disease itself”.

“We are very excited about the positive results of the NUC-5 trial, which was the largest clinical trial on PSC to date which compared biopsies from patients before and after treatment” said Dr. Kai Pinkernell, Managing Director Science and Innovation for Dr. Falk Pharma. “A trial of this duration and involvement is a major undertaking, and we thank all of the participating patients, investigators, and trial staff for their dedication to this trial”.

About norucholic acid

Norucholic acid is an engineered bile acid derivative. Unlike endogenous bile acids, it undergoes no meaningful amidation with glycine or taurine, allowing NCA to be absorbed from bile by cholangiocytes and subsequently re-secreted into bile by hepatocytes in a process called cholehepatic shunting. This together with putative direct anti-inflammatory and anti-fibrotic mechanisms are thought to confer protective effects in PSC. In a previous phase 2 trial, 12 weeks of treatment with NCA was shown to significantly reduce levels of alkaline phosphatase (ALP).

About NUC-5

NUC-5 is a randomized, double-blind, placebo-controlled trial enrolling 301 patients with biopsy-confirmed PSC and levels of ALP at least 1.5-fold greater than the upper limit of normal (ULN). The combined primary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (Ludwig classification). The key secondary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (modified Nakanuma staging).

At week 96, 15.1% of patients receiving NCA achieved the primary endpoint compared to 4.2% of placebo patients (p = 0.0048). Similarly, 15.1% of NCA patients versus 5.1% of placebo patients achieved the key secondary endpoint (p = 0.0086). NCA treatment led to improvement by at least 1 Ludwig stage for 25.2% of NCA patients compared to 10.5% of placebo patients (p = 0.0217). Furthermore, worsening by at least one Ludwig stage was observed in 40.4% of placebo patients compared to 20.3% of NCA patients (p = 0.0069). Blood levels of multiple liver enzymes improved under NCA but not placebo. NCA was well tolerated, with similar rates of serious adverse events between the two arms.

NUC-5 is still ongoing, with patients receiving continuous double-blind treatment with either NCA or placebo for an additional 96 weeks. Additional results will be reported after the conclusion of all 192 weeks of double-blind treatment. Patients completing all 192 weeks of double-blind treatment will have the option of receiving open-label treatment with NCA for up to 72 weeks.

Read the abstract here (LBO-001)

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1400 individuals globally and 340 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com


Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis


THỦ THUẬT HAY

Cách chỉnh độ sắc nét cho laptop có màn hình độ phân giải cao

Để có những hình ảnh hiển thị trên laptop chất lượng nhất và sắc nét nhất, bạn cần tìm cách chỉnh độ sắc nét cho laptop có màn hình độ phân giải cao sao cho chuẩn xác nhất và phù hợp với màn hình máy tính, mắt thẩm mỹ

Hướng dẫn cách tắt quảng cáo trên iPhone với Adblock Mobile

Adblock Mobile là một ứng dụng chặn quảng cáo hiệu quả trên iPhone, giúp bạn loại bỏ quảng cáo phiền phức khi lướt web hay sử dụng ứng dụng. Dưới đây là hướng dẫn cách tắt quảng cáo trên iPhone với Adblock Mobile

Cách cập nhật iOS 15 chính thức từ iOS 15 Beta, có bị lỗi gì không...?

Nhiều bạn vẫn còn thắc mắc về những cách cập nhật lên iOS 15 chính thức mới nhất. Và trong bài viết này mình sẽ giải đáp cho bạn về cập nhật iOS 15 chính thức.

[Google I/O 2018] Cài đặt Android P beta trên các smartphone trong danh sách hỗ trợ

Nếu điện thoại của bạn là Google Pixel thì rất dễ dàng, chỉ cần truy cập vào trang web Chương trình Android beta của Google và đăng ký dùng thử Android P, nếu bạn mở trang web này trên máy tính thì cần đảm bảo tài

Cách sử dụng Driver Easy để cập nhật Driver cho máy tính

Driver Easy sẽ tự động tìm kiếm, sao lưu và cập nhật Driver còn thiếu cũng như lỗi thời trên máy tính vô cùng nhanh chóng. Ngoài ra, còn giúp người dùng kiểm tra thông tin liên quan tới hệ thống như: Hệ điều hành, bộ

ĐÁNH GIÁ NHANH

Đánh giá camera Redmi Note 4: Có cải thiện nhưng chưa đủ

Chưa bao giờ cơn sốt Xiaomi bước chân vào Việt Nam lại hot đến vậy, điển hình là bài Redmi Note 4 của mình nhận được nhiều sự quan tâm của người...

Đánh giá hiệu năng Zenfone 5: Sản phẩm đáng chú ý tầm giá 9.9. triệu

Nhìn qua bảng cấu hình chúng ta sẽ không thấy yếu tố nào quá nổi bật, vì ở phân khúc tầm trung đã có những sản phẩm chạy Snapdragon 660 nên con chip 636 không thực sự được chú ý. Nhiều người cho rằng đây chỉ là một bản

Vivo X70 Pro có gì đặc biệt để có thể chinh phục được người dùng Việt?

Vivo X70 Pro đã chính thức ra mắt và chuẩn bị lên kệ tại Việt Nam. Đây là mẫu smartphone cao cấp nhất của Vivo hiện nay. Vậy Vivo X70 Pro có gì đặc biệt để thuyết phục được người dùng Việt xuống tiền? Hãy cùng mình đi